The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(E)-5-(naphthalen-2-yl)-N'-(3-nitrobenzylidene)-1H-pyrazole-3-carbohydrazide ID: ALA4866324
PubChem CID: 9565050
Max Phase: Preclinical
Molecular Formula: C21H15N5O3
Molecular Weight: 385.38
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: O=C(N/N=C/c1cccc([N+](=O)[O-])c1)c1cc(-c2ccc3ccccc3c2)[nH]n1
Standard InChI: InChI=1S/C21H15N5O3/c27-21(25-22-13-14-4-3-7-18(10-14)26(28)29)20-12-19(23-24-20)17-9-8-15-5-1-2-6-16(15)11-17/h1-13H,(H,23,24)(H,25,27)/b22-13+
Standard InChI Key: GSRZNGDNNSEOTR-LPYMAVHISA-N
Molfile:
RDKit 2D
29 32 0 0 0 0 0 0 0 0999 V2000
28.9882 -31.0532 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.9871 -31.8728 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.6951 -32.2817 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.6933 -30.6444 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.4020 -31.0496 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.4027 -31.8686 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.1113 -32.2757 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.8195 -31.8649 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.8148 -31.0428 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.1057 -30.6394 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.5191 -30.6275 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.2677 -30.9553 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.8108 -30.3447 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.3979 -29.6394 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
32.5996 -29.8143 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
34.6240 -30.4251 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.9609 -31.1696 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
35.1003 -29.7611 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
35.9135 -29.8416 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
36.3898 -29.1775 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.2030 -29.2580 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.5377 -30.0046 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.3501 -30.0854 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.8273 -29.4209 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.4862 -28.6736 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.6748 -28.5965 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.9576 -28.0054 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
39.7711 -28.0830 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
38.6180 -27.2620 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
6 7 1 0
7 8 2 0
8 9 1 0
9 10 2 0
10 5 1 0
11 12 2 0
12 13 1 0
13 14 2 0
14 15 1 0
15 11 1 0
9 11 1 0
13 16 1 0
16 17 2 0
16 18 1 0
18 19 1 0
19 20 2 0
20 21 1 0
21 22 2 0
22 23 1 0
23 24 2 0
24 25 1 0
25 26 2 0
26 21 1 0
27 28 1 0
27 29 2 0
25 27 1 0
M CHG 2 27 1 28 -1
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 385.38Molecular Weight (Monoisotopic): 385.1175AlogP: 3.90#Rotatable Bonds: 5Polar Surface Area: 113.28Molecular Species: NEUTRALHBA: 5HBD: 2#RO5 Violations: ┄HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 9.06CX Basic pKa: 1.64CX LogP: 4.15CX LogD: 4.14Aromatic Rings: 4Heavy Atoms: 29QED Weighted: 0.31Np Likeness Score: -1.95
References 1. Butler KJ, Castro AA, Dwyer TS, Hardwick LM, Iacino MC, Manore SG, Mays KM, McGlade CA, Hair LN, Parker EW, Smith MR, Turnow MT, Wilson MR, Woodson SR, Cotham WE, Walla MD, Hurlbert JC, Christian Grattan T.. (2021) Design, synthesis and analysis of novel sphingosine kinase-1 inhibitors to improve oral bioavailability., 50 [PMID:34418572 ] [10.1016/j.bmcl.2021.128329 ]